HIGHLIGHTS
- who: . et al. from the East China University of Science and have published the paper: Recent advances in nano-drug delivery systems for synergistic antitumor immunotherapy, in the Journal: (JOURNAL)
- what: The lack of immunogenicity and subsequent insufficient antitumor immune_response is a major reason for the lack of efficacy of several immunotherapies (Pilla et_al, 2018).
- how: Previous data showed that the remission rate of Keytruda singledrug therapy was 47% and the complete remission rate was 14%. The results showed that the median progression-free survival of the combined group was 6.8 months . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.